基本信息
views: 191
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
His major interests focus on physical pharmacy. Specifically, he has designed novel drug delivery systems with further exploration of the underlying mechanisms overcoming the key physiological barriers. He has now published more than 70 peer-reviewed papers in international journals, including Science Advances, Nature Communications, PNAS, Advanced Functional Materials, Advanced Science, ACS Nano, Nano Letters, Biomaterials, Journal of Controlled Release. He has also participated in writing and editing 5 books. In the aspect of translational medicine, Prof. Gan has rationally designed a series of innovative preparations with good druggability, some of which are now undergoing clinical trials. Up to now, he holds 35 authorized patents, 15 clinical approvals for new drugs, and 5 commercial formulations.
Research Interests
Papers共 152 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CHEMICAL ENGINEERING JOURNAL (2024): 148120
Acta Pharmaceutica Sinica Bno. 5 (2024): 2006-2025
Li Liang,Ning Wang,Xiang Li,Zhuan Zhang, Zhu Zhu,Yan Zhuo,Xiaohe Jiang,Jie Wang, Cong Guo, Shiyan Guo,Pinghong Zhou,Yan Zhu,
Nano Today (2024): 102377
Nature Communicationsno. 1 (2024): 1-20
Chinese Journal of Pharmaceuticalsno. 10 (2023)
Yihan Zhou, Duo Gao,Yaying Wang,Li Liang,Qingyu Zhang, Wenwen Han,Jie Wang,Chunliu Zhu,Xinxin Zhang,Yong Gan
Chinese Chemical Lettersno. 6 (2023): 108967-108967
Load More
Author Statistics
#Papers: 158
#Citation: 5154
H-Index: 40
G-Index: 68
Sociability: 6
Diversity: 1
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn